Dyadic International (NQ: DYAI )
2.000 +0.020 (+1.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Press Releases about Dyadic International
Dyadic to Participate at Two Industry Events in May
May 10, 2023
Dyadic to Present at World Vaccine Congress Washington 2023
March 30, 2023
Dyadic to Participate in Two Upcoming Investor Conferences
February 02, 2023
Dyadic Announces Sale of Equity Interest in Alphazyme
January 19, 2023
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA...
Dyadic to Present at Upcoming Industry and Investor Events in November
November 07, 2022
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 12, 2021
- Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies,...
Dyadic to Report Second Quarter 2021 Financial Results
July 29, 2021
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,...
Topics Regulatory Compliance
Dyadic to Present at Upcoming Events
May 24, 2021
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its...
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 13, 2021
- Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial - Goal of validating that C1 produced proteins are safe in humans and to...